drugset / Trial / NCT00002131

A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

NCT00002131 ↗

Phase 2 Completed 28 enrolled Otsuka America Pharmaceutical
Open-labelTreatment

Summary

To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposi's sarcoma.

Timeline

Start
—
Primary completion
—
Completion
—

Publications

  • Background Petit RG, Miles S, Magpantay L, Mitsuyasu R. Vesnarinone inhibits AIDS-KS cells in culture. Int Conf AIDS. 1994 Aug 7-12;10(1):169 (abstract no PB0104)

Drugs

EvaluationDrugModalityDoseRoute
Subject Vesnarinone Small molecule — —